PE20141295A1 - Agentes de reversion anticoagulante - Google Patents

Agentes de reversion anticoagulante

Info

Publication number
PE20141295A1
PE20141295A1 PE2014000763A PE2014000763A PE20141295A1 PE 20141295 A1 PE20141295 A1 PE 20141295A1 PE 2014000763 A PE2014000763 A PE 2014000763A PE 2014000763 A PE2014000763 A PE 2014000763A PE 20141295 A1 PE20141295 A1 PE 20141295A1
Authority
PE
Peru
Prior art keywords
guanidine
amino
compounds
pentanoylamine
piperazin
Prior art date
Application number
PE2014000763A
Other languages
English (en)
Inventor
Solomon S Steiner
Bryan E Laulicht
Sasha H Bakhru
Edith Mathiowitz
Original Assignee
Perosphere Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perosphere Inc filed Critical Perosphere Inc
Publication of PE20141295A1 publication Critical patent/PE20141295A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Abstract

SE REFIERE A COMPUESTOS DE FORMULA Y-M-X-L-A-L'-X'-M'-Y' DONDE A ES UN ANILLO CARBOCICLICO O HETEROCICLICO AROMATICO O NO AROMATICO TAL COMO PIPERAZINA, DICETOPIPERAZINA, ENTRE OTROS; L Y L' SON CADA UNO ALQUILENO(C1-C6); X Y X' SON CADA UNO ESTERES, AMIDAS O CETONAS; M Y M' ESTAN AUSENTES O SON UN ENLACE; Y E Y' SON CADA UNO UN RESTO QUE CONTIENE GRUPOS CATIONICOS TALES COMO -NH-C(NH2)=NH, NH2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (3-{4-[3-(2-AMINO-5-GUANIDINO-PENTANOILAMINO)-PROPIL]-PIPERAZIN-1-IL}-PROPIL)-AMIDA DEL ACIDO 2-AMINO-5-GUANIDINO-PENTANOICO; {5-[(2-AMINO-5-GUANIDINO-PENTANOILAMINO)-METIL]-PIPERAZIN-2-ILMETIL}-AMIDA DEL ACIDO 2-AMINO-5-GUANIDINO-PENTANOICO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS REVIERTEN PARCIAL O COMPLETAMENTE LOS EFECTOS ANTICOAGULANTES DE INHIBIDORES DE LA COAGULACION TALES COMO HEPARINA NO FRACCIONADA, HEPARINA DE BAJO PESO MOLECULAR, ENTRE OTROS
PE2014000763A 2011-11-29 2012-11-29 Agentes de reversion anticoagulante PE20141295A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161564559P 2011-11-29 2011-11-29
US201261614292P 2012-03-22 2012-03-22
US201261641698P 2012-05-02 2012-05-02
US201261666291P 2012-06-29 2012-06-29

Publications (1)

Publication Number Publication Date
PE20141295A1 true PE20141295A1 (es) 2014-10-01

Family

ID=47430065

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000763A PE20141295A1 (es) 2011-11-29 2012-11-29 Agentes de reversion anticoagulante

Country Status (35)

Country Link
US (4) US9522892B2 (es)
EP (1) EP2785700B1 (es)
JP (1) JP6134731B2 (es)
KR (1) KR101892330B1 (es)
CN (1) CN104080772B (es)
AP (1) AP2014007662A0 (es)
AR (1) AR089020A1 (es)
AU (1) AU2012345975B2 (es)
BR (1) BR112014012892B1 (es)
CA (1) CA2856540C (es)
CL (1) CL2014001399A1 (es)
CO (1) CO6990738A2 (es)
CR (1) CR20140310A (es)
CY (1) CY1117414T1 (es)
DK (1) DK2785700T3 (es)
EA (1) EA027603B1 (es)
EC (1) ECSP14006696A (es)
ES (1) ES2569674T3 (es)
HK (1) HK1202858A1 (es)
HR (1) HRP20160513T1 (es)
HU (1) HUE027452T2 (es)
IL (1) IL232788B (es)
ME (1) ME02424B (es)
MX (1) MX349514B (es)
PE (1) PE20141295A1 (es)
PH (1) PH12014501176B1 (es)
PL (1) PL2785700T3 (es)
PT (1) PT2785700E (es)
RS (1) RS54738B1 (es)
SG (1) SG11201402713WA (es)
SI (1) SI2785700T1 (es)
SM (1) SMT201600161B (es)
UA (1) UA116336C2 (es)
WO (1) WO2013082210A1 (es)
ZA (1) ZA201404793B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069844A1 (en) * 2013-11-08 2015-05-14 Perosphere Inc. Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds
AU2018365257B2 (en) * 2017-11-13 2021-05-13 Maximum Fidelity Surgical Simulations, LLC Reconstitution of post mortem circulation, specialized methods and procedures
JP2021529765A (ja) 2018-06-29 2021-11-04 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ａｘｌ／ｍｅｒ阻害剤の製剤
US11716989B2 (en) 2019-04-16 2023-08-08 Maximum Fidelity Surgical Simulations, LLC Cadaver preservation systems and methods
US11915610B2 (en) 2019-05-15 2024-02-27 Maximum Fidelity Surgical Simulations, LLC Cadaverous heart model
CN112010930B (zh) * 2019-05-28 2022-08-02 首都医科大学 Rgd修饰的五环哌嗪二酮及其制备和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3678157A (en) * 1968-10-23 1972-07-18 Oreal Hair treatment compositions containing polycondensable compounds
IL115420A0 (en) * 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
US6069232A (en) * 1995-10-02 2000-05-30 Hoechst Marion Roussel, Inc. Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors
US6080852A (en) 1996-06-27 2000-06-27 The Perkin-Elmer Corporation 4,7-dichlororhodamine dyes
CA2268381A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
SI20115A (sl) * 1997-04-07 2000-06-30 Axys Pharmaceuticals, Inc. Spojine in sestavki za zdravljenje bolezni, povezanih z aktivnostjo serinskih proteaz, zlasti triptaze
FR2781221B1 (fr) * 1998-07-17 2000-10-13 Lafon Labor Piperazinones substituees en alpha
CA2348740A1 (en) * 1998-12-23 2000-07-06 Ruth R. Wexler Thrombin or factor xa inhibitors
CN1152023C (zh) 1999-05-19 2004-06-02 法玛西雅公司 作为抗凝血剂的取代的多环芳基与杂芳基尿嘧啶
CA2412345A1 (en) * 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
JP2004501077A (ja) 2000-04-17 2004-01-15 ファルマシア・コーポレーション 凝固カスケードの選択的阻害に有用な多環式アリールおよびヘテロアリール置換１，４−キノン
WO2002002519A2 (en) * 2000-06-29 2002-01-10 Bristol-Myers Squibb Pharma Company THROMBIN OR FACTOR Xa INHIBITORS
US6969715B2 (en) 2001-10-03 2005-11-29 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
JP2005529860A (ja) 2002-03-27 2005-10-06 グラクソ　グループ　リミテッド ジアミノ酸−アミノ酸−ポリアミンに基づいたジェミニ界面活性剤化合物
EP1550455A1 (en) * 2002-05-23 2005-07-06 Chugai Seiyaku Kabushiki Kaisha Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation
GB0214122D0 (en) 2002-06-19 2002-07-31 Eastman Kodak Co High contrast photographic element containing a polyhydrazide nucleating agent
SE0400014D0 (sv) * 2004-01-08 2004-01-08 Astrazeneca Ab Heterocyclic derivatives
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
EP2915564B1 (en) * 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
GB2476643B (en) 2009-12-23 2012-11-14 Haomamedica Ltd 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
MA34978B1 (fr) 2011-03-30 2014-03-01 Boehringer Ingelheim Int Antidotes pour anticoagulants

Also Published As

Publication number Publication date
US20170056396A1 (en) 2017-03-02
PT2785700E (pt) 2016-06-02
AU2012345975A1 (en) 2014-05-29
RS54738B1 (sr) 2016-10-31
CO6990738A2 (es) 2014-07-10
HK1202858A1 (en) 2015-10-09
ZA201404793B (en) 2015-04-29
SI2785700T1 (sl) 2016-09-30
JP2014534270A (ja) 2014-12-18
CL2014001399A1 (es) 2014-11-03
NZ625337A (en) 2016-11-25
BR112014012892A2 (pt) 2017-06-13
ES2569674T3 (es) 2016-05-12
CY1117414T1 (el) 2017-04-26
BR112014012892A8 (pt) 2021-06-08
IL232788B (en) 2018-05-31
US9877961B2 (en) 2018-01-30
EA027603B1 (ru) 2017-08-31
MX2014006349A (es) 2014-09-04
SG11201402713WA (en) 2014-06-27
MX349514B (es) 2017-08-02
AP2014007662A0 (en) 2014-05-31
AR089020A1 (es) 2014-07-23
CN104080772A (zh) 2014-10-01
KR20140107259A (ko) 2014-09-04
CA2856540C (en) 2018-04-03
SMT201600161B (it) 2016-07-01
CR20140310A (es) 2014-08-20
PH12014501176A1 (en) 2014-09-01
DK2785700T3 (en) 2016-06-13
HUE027452T2 (en) 2016-09-28
US9522892B2 (en) 2016-12-20
BR112014012892B1 (pt) 2022-12-20
PH12014501176B1 (en) 2014-09-01
CN104080772B (zh) 2016-10-05
US20130137702A1 (en) 2013-05-30
JP6134731B2 (ja) 2017-05-24
CA2856540A1 (en) 2013-06-06
US20210169874A1 (en) 2021-06-10
WO2013082210A1 (en) 2013-06-06
EP2785700A1 (en) 2014-10-08
PL2785700T3 (pl) 2016-09-30
AU2012345975B2 (en) 2016-12-15
ME02424B (me) 2016-09-20
HRP20160513T1 (hr) 2016-07-15
UA116336C2 (uk) 2018-03-12
ECSP14006696A (es) 2015-06-30
IL232788A0 (en) 2014-08-03
EA201490823A1 (ru) 2015-01-30
US20180207152A1 (en) 2018-07-26
KR101892330B1 (ko) 2018-08-27
EP2785700B1 (en) 2016-03-09

Similar Documents

Publication Publication Date Title
PE20141295A1 (es) Agentes de reversion anticoagulante
PE20130281A1 (es) Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae
EA201492285A1 (ru) Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar)
PE20130382A1 (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
CY1118973T1 (el) Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων
EA201492281A1 (ru) Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
EA201500557A1 (ru) Антигельминтные соединения, композиции и способы их применения
RS54782B1 (sr) Novi heterociklični derivati i njihova upotreba u tretmanu neuroloških poremećaja
CO6210771A2 (es) Moduladores 2-aminopirimidina del receptor de histamina h4
AR092503A1 (es) 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b
EA201390877A1 (ru) Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
UY29184A1 (es) Derivados de sulfonilbencimidazol
EA201201033A1 (ru) Циклический амин и акарицид
PE20140471A1 (es) Moduladores de la via del complemento y usos de los mismos
BR112014023384A8 (pt) inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos.
AR098147A1 (es) Composiciones herbicidas que contienen amidas de ácido n-(1,3,4-oxadiazol-2-il)arilcarboxílico
EA201591195A1 (ru) Новые хинолоновые производные
PE20091093A1 (es) Compuesto heterociclico que contiene nitrogeno y su uso
AR074676A1 (es) Derivados de isooxazol como antagonistas de receptores de acido lisofosfatidico, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la actividad fisiologica de lpa.
CO7350652A2 (es) Piridina-2-amidas útiles como agonistas de cb2
BR112014010407A2 (pt) compostos de azetidina, composições e seu uso como inibidores de hidrolase de epóxido solúvel
ECSP11011427A (es) Piperidinas sustituidas como antagonistas de ccr3.
AR111756A1 (es) 4-difluorometilbenzoilamidas de acción herbicida
EA201492283A1 (ru) Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
CO6741154A2 (es) Compuestos de triazolopiridina

Legal Events

Date Code Title Description
FG Grant, registration